lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

A Randomised Trial of Intensive versus Standard Blood-Pressure Control in Patients with a History of Stroke: The RESPECT Study

119 Pages Posted: 14 Feb 2019

See all articles by Kazuo Kitagawa

Kazuo Kitagawa

Tokyo Womens Medical University - Department of Neurology

Yasumasa Yamamoto

Kyoto Katsura Hospital

Hisatomi Arima

Fukuoka University

Toshiki Maeda

Fukuoka University

Norio Sunami

Fukuzumi Hospital

Takao Kanzawa

Institute of Brain and Blood Vessel Mihara Memorial Hospital

Kazuo Eguchi

Hanyu General Hospital

Kenji Kamiyama

Nakamura Memorial Hospital

Kazuo Minematsu

National Cerebral and Cardiovascular Centre

Shinichiro Ueda

University of Ryukyu

Hiromi Rakugi

Osaka University

Yusuke Ohya

University of Ryukyu

Takahide Kohro

Jichi Medical University

Koji Yonemoto

Ryukyu School of Medicine

Yasushi Okada

Kyushu Medical Center Clinical Research Institute

Jitsuo Higaki

Iwatsuki-Minami Hospital

Norio Tanahashi

Saitama University - Saitama Medical Center

Genjiro Kimura

Cardio-Renal and Health Research Institute

Satoshi Umemura

Yokohama Rosai Hospital

Masayasu Matsumoto

Sakai City Medical Center

Kazuaki Shimamoto

Japan Health Care College

Sadayoshi Ito

Tohoku University - Division of Nephrology, Endocrinology and Vascular Medicine

Takao Saruta

Keio University; Keio University

Kazuyuki Shimada

Shin-Oyama City Hospital

The Recurrent Stroke Prevention Clinical Outcome (RESPECT) Study Group

More...

Abstract

Background: Lowering of blood pressure after stroke reduces the risk of recurrent stroke, but the optimum target blood pressure level is unknown. We evaluated the effects of intensive versus standard blood-pressure-lowering regimen on the rate of recurrent stroke in patients with recent stroke.

Methods: This randomised open-label trial included eligible patients in Japan who had recent, CT- or MRI-defined symptomatic ischaemic or haemorrhagic stroke. Patients were recruited between October 2010 and December 2015, and were randomly assigned 1:1 to blood pressure control to less than 140/90 mmHg, standard treatment, or to levels of less than 120/80 mmHg, intensive treatment, according to a parallel design. The primary endpoint was stroke including ischaemic stroke and intracerebral haemorrhage. Analysis was done by intention to treat.

Findings: The trial was stopped early because of cessation of funding after the enrolment of 1263 out of the planned 2000 patients. Of these patients, 630 in the standard-treatment group and 633 in the intensive-treatment group were followed up for a mean of 3.9 (SD 1.5) years. Mean age was 67 (SD 8.8) years. After 1 year, the mean blood pressure was 132.0/77.5 mmHg (95% CI 130.9-133.0/76.6-78.3) in the standard target group and 123.7/72.8 mmHg (95% CI 122.6-124.8/72.0-73.7) in the intensive target group. Ninety-one first recurrent strokes occurred. Non-significant rate reductions were seen for all cases of stroke (hazard ratio 0.73, 95% CI 0.49-1.11, p=0.145); however, when this finding was pooled with the results of prior trials of intensive blood pressure lowering for secondary stroke prevention, the pooled risk ratio favoured intensive blood pressure control (relative risk 0.78, 95% CI 0.64-0.96, p= 0.016).

Interpretation: Intensive blood pressure lowering does not significantly reduce stroke recurrence. The non-significant findings might be attributable to insufficient statistical power due to early termination of the trial or the modest difference in blood pressure level between groups. Nevertheless, the updated meta-analysis including this trial supports the target blood pressure of less than 130/80 mmHg in the secondary prevention of stroke.

Clinical Trial Number: This study was registered with ClinicalTrials.gov, number NCT01198496.

Funding Statement: Merck and Co. Inc., Bristol-Myers Squibb Company, Towa Pharmaceutical Co., Ltd, and Omron Corporation.

Declaration of Interests: KK reports grants and personal fees from Daiichi Sankyo, grants and personal fees from Bayer Inc., grants and personal fees from Takeda Pharmaceutical, grants and personal fees from Nippon Boehringer Ingelheim, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Sumitomo Dainippon Pharma, grants and personal fees from Astellas Pharma, grants and personal fees from Sanofi, outside the submitted work; YY has nothing to disclose; HA reports personal fees from Bayer, personal fees from Daiichi Sankyo, personal fees from Fukuda Denshi, personal fees from Kyowa Kirin, personal fees from Takeda, outside the submitted work; TM has nothing to disclose; NS has nothing to disclose; TK has nothing to disclose; KM has nothing to disclose; KeKa has nothing to disclose; KM reports personal fees from Bayer Yakuhin, personal fees from Otsuka Pharmaceutical, personal fees from Boehringer-Ingelhaeim, personal fees from AstraZeneca, personal fees from Pfizer, personal fees from Mitsubishi Tanabe Pharma Cooperation, personal fees from Japan Stryker, personal fees from Kowa, personal fees from Nihon Medi-Physics Co., personal fees from BM from Bayer Yakuhin, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Mochida Pharmaceutical, grants and personal fees from Nippon Boehringer Ingelheim, grants and personal fees from Takeda Pharmaceutical, grants from Mitsubishi Tanabe Pharma, grants from Novartis Pharma, grants from Otsuka Pharmaceutical, grants from Pfizer Japan, grants from Shionogi & Co, grants from Teijin Pharma, outside the submitted work; YO reports grants and personal fees from Takeda Pharma, grants and personal fees from Daiichi-Sankyo, grants from Novartis Pharma, grants from Asterasu, personal fees from Dainippon-Sumitomo, personal fees from MSD, grants and personal fees from Bayer, grants and personal fees from Pfizer, grants and personal fees from Bohelinger, outside the submitted work; TK has nothing to disclose; YaOk has nothing to disclose; NT has nothing to disclose; GK has nothing to disclose; SaUm reports grants from Dainippon-Sumitomo, grants from Asteras, grants from Pfizer, grants from Nippon Boehringer Ingelheim, grants from Daiichi-Sankyo, grants from Takeda, personal fees from Nippon Boehringer Ingelheim, personal fees from Takeda, outside the submitted work; MM reports personal fees from Kowa Pharmaceutical Co Ltd, personal fees from Takeda Pharmaceutical Co Ltd, personal fees from Bayer Yakuhin, Ltd, personal fees from Sanofi KK, personal fees from Daiichi Sankyo Co0 Ltd, personal fees from Otsuka Pharmaceutical Co Ltd, personal fees from Astellas Pharma Inc, personal fees from Astra Zeneca KK, personal fees from Mochida Pharmaceutical Co, Ltd, personal fees from Sumitomo Dainippon Pharma Co Ltd, personal fees from Amgen Astellas BioPharma KK, personal fees from Esai Co, Ltd, personal fees from Pfizer Japan Inc, outside the submitted work; KS reports personal fees from Takeda, personal fees from Sumitomo Dainippon Pharma Co. Ltd., personal fees from MSD, personal fees from Astellas Pharma, personal fees from Boehringer-Ingelheim, personal fees from Bayer Yakuhin, outside the submitted work; SI reports personal fees from MSD, during the conduct of the study; grants and personal fees from Daiichi Sankyo, grants and personal fees from Takeda, grants and personal fees from Astellas, personal fees from Boehilinger-Ingerhaim, outside the submitted work; TS has nothing to disclose; KS reports personal fees from Dainippon-Sumitomo LTD, and Daiichi-Sankyo.

Ethics Approval Statement: Participation required written informed consent, and approval was provided by the local ethics committees for human research.

Suggested Citation

Kitagawa, Kazuo and Yamamoto, Yasumasa and Arima, Hisatomi and Maeda, Toshiki and Sunami, Norio and Kanzawa, Takao and Eguchi, Kazuo and Kamiyama, Kenji and Minematsu, Kazuo and Ueda, Shinichiro and Rakugi, Hiromi and Ohya, Yusuke and Kohro, Takahide and Yonemoto, Koji and Okada, Yasushi and Higaki, Jitsuo and Tanahashi, Norio and Kimura, Genjiro and Umemura, Satoshi and Matsumoto, Masayasu and Shimamoto, Kazuaki and Ito, Sadayoshi and Saruta, Takao and Shimada, Kazuyuki and Study Group, The Recurrent Stroke Prevention Clinical Outcome (RESPECT), A Randomised Trial of Intensive versus Standard Blood-Pressure Control in Patients with a History of Stroke: The RESPECT Study (October 11, 2018). Available at SSRN: https://ssrn.com/abstract=3284180 or http://dx.doi.org/10.2139/ssrn.3284180

Kazuo Kitagawa (Contact Author)

Tokyo Womens Medical University - Department of Neurology ( email )

8-1 Kawada-cho
Tokyo, 162-8666
Japan

Yasumasa Yamamoto

Kyoto Katsura Hospital

Nishikyo
Japan

Hisatomi Arima

Fukuoka University

Fukuoka 814-0180
Japan

Toshiki Maeda

Fukuoka University

Fukuoka 814-0180
Japan

Norio Sunami

Fukuzumi Hospital

Matsuyama
Japan

Takao Kanzawa

Institute of Brain and Blood Vessel Mihara Memorial Hospital

Isesaki
Japan

Kazuo Eguchi

Hanyu General Hospital

Hanyu
Japan

Kenji Kamiyama

Nakamura Memorial Hospital

Sapporo
Japan

Kazuo Minematsu

National Cerebral and Cardiovascular Centre

5-7-1 Fujishiro-da
Suita, 565-8565
Japan

Shinichiro Ueda

University of Ryukyu

Okinawa
Japan

Hiromi Rakugi

Osaka University

1-1 Yamadaoka
Suita
Osaka, 565-0871
Japan

Yusuke Ohya

University of Ryukyu

Okinawa
Japan

Takahide Kohro

Jichi Medical University

Shimotsuke
Japan

Koji Yonemoto

Ryukyu School of Medicine

Nakagamigunn
Japan

Yasushi Okada

Kyushu Medical Center Clinical Research Institute

Chuo
Japan

Jitsuo Higaki

Iwatsuki-Minami Hospital

Japan

Norio Tanahashi

Saitama University - Saitama Medical Center

Japan

Genjiro Kimura

Cardio-Renal and Health Research Institute

Nagoya
Japan

Satoshi Umemura

Yokohama Rosai Hospital

Yokohama
Japan

Masayasu Matsumoto

Sakai City Medical Center

Sakai
Japan

Kazuaki Shimamoto

Japan Health Care College

Sapporo
Japan

Sadayoshi Ito

Tohoku University - Division of Nephrology, Endocrinology and Vascular Medicine

Sendai
Japan

Takao Saruta

Keio University

2-15-45 Mita
Minato-ku
Tokyo, 108-8345
Japan

Keio University

2-15-45 Mita
Minato-ku
Tokyo, 108-8345
Japan

Kazuyuki Shimada

Shin-Oyama City Hospital

Oyama
Japan

No contact information is available for The Recurrent Stroke Prevention Clinical Outcome (RESPECT) Study Group

Click here to go to TheLancet.com

Paper statistics

Abstract Views
315
Downloads
30